Why Participate in Clinical Research
Importance of Clinical Research
What we Offer
Currently Enrolling for the following Clinical trials:
CLOU: A randomized, double- blind, double-dummy, parallel group study, comparing the efficacy and safety of Remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis by extended treatment with open-labels Remibrutinib.
Ozanimod: A phase 3B, multicenter, open-label study to evaluate the immune response to, and the safety of, vaccines in participants with relapsing forms of Multiple Sclerosis who receive oral ozanimod compared to non-pegylated Interferon-B or no disease modifying therapy
T-Scan: This multicenter study will include up to 300 patients, aimed at obtaining biologic samples from up to 300 patients with autoimmune disease. The specific autoimmune diseases under study include; Crohn’s Disease, Ulcerative Colitis, Celiac Disease, Ankylosing Spondylitis, Multiple Sclerosis, Scleroderma, and Systemic Sclerosis. Enrollment will continue until biologic samples are obtained from 300 patients, with a maximum of 60 patients with the same autoimmune disease diagnosis.
Otsuka: A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-design study to assess the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of agitation in patients with dementia of the Alzheimer’s type.
Otsuka 303 extension: The objectives of the study are to evaluate the long-term safety and maintenance of efficacy of the AVP-786 for the treatment of agitation in patients with dementia of Alzheimer’s type.
GemVaxx: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Prospective, 52-Week, Phase 2 Clinical Study to Evaluate the Safety and Efficacy of GV1001 Administered Subcutaneously for the Treatment of Mild to Moderate Alzheimer’s Disease
Cypress: A Phase 3, Multi-center, Randomized Withdrawal and Long-Term Extension Study of Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Participants with Multiple System Atrophy
Why Choose Us
If you have a disease or illness that’s genetic, your participation could end up helping your loved ones by making new treatments available and advancing scientists’ understanding of the disease or illness. The study could even be the one that leads to a cure.
Taking part in a clinical trial may give you access to experimental, cutting-edge treatment options. Plus, you will have access to a medical team that carefully monitors your disease and your overall health.
Have you ever considered participating in Clinical Research?
Neurostudies Inc. has served the communities of Charlotte and surrounding counties for more than 20 years. We are currently offering studies for patients with Multiple Sclerosis, Parkinson’s Disease, Mild Cognitive Impairment, Alzheimer’s Disease, and Orthostatic Hypotension. There is no cost for the participant for either the initial evaluation or for the trial if eligible. We also offer free memory assessments.
How do you get started as a participant in a clinical trial?
We can answer any questions you may have and help to explain the Clinical Research experience you will have at Neurostudies Inc.
Get started as a Participant.
4161 Tamiami Trail
Port Charlotte, Florida 33952